Amarin Corp Plc (AMRN)

[Biobillionair]

FDA has rejected a prior EPA/DHA combo that raised LDL in treatment of 200-500. Extremely unlikely a combo would be approved with a mono product that increases LDL.

This is Pronova territory and likely not patentable again. The only way this will help AZN is if they end up with Amarin. I don't see PFE losing the bid.